Shares of Skye Bioscience (SKYE) and Corbus Pharmaceuticals (CRBP) are sinking after Novo Nordisk reported Phase 2 weight loss data for monlunabant, which targets type 1 cannabinoid receptors. Skye and Corbus are developing drugs that use a similar approach to monlunabant.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE: